Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know

Area of Science:

• Oncology
• Endocrinology
• Bone Metabolism

Background:

• Breast cancer is a leading cause of mortality in women globally.
• Endocrine therapy, particularly aromatase inhibitors (AIs), is a standard treatment for hormone-sensitive breast cancer in postmenopausal women.
• AIs improve survival but are associated with adverse effects, including accelerated bone loss in a subset of patients.

Purpose of the Study:

• To review clinical and biochemical factors linked to decreased bone mineral density in postmenopausal women undergoing AI therapy.
• To emphasize the importance of identifying susceptible patients for early intervention and personalized bone health management.
• To address the limited data from international trials concerning AI side effects in diverse populations, particularly in developing countries.

Main Methods:

• Literature review focusing on clinical trials and observational studies of aromatase inhibitors in postmenopausal breast cancer patients.
• Analysis of factors associated with bone mineral density reduction during endocrine therapy.
• Synthesis of information relevant to surgical management of endocrine therapy side effects.

Main Results:

• A subset of postmenopausal women experiences accelerated bone loss while on AI therapy.
• Specific clinical and biochemical factors are associated with this bone mineral density decrease, though not fully identified.
• Existing international data on AIs primarily reflects North American and European populations.

Conclusions:

• Early identification of postmenopausal women susceptible to AI-induced bone loss is critical for preventing adverse skeletal events.
• Surgeons managing endocrine therapy must be aware of and prepared to address AI-related side effects, including bone health.
• Personalized management strategies based on identified risk factors are essential for optimizing bone health in breast cancer patients receiving AIs.